Suspected Gastroparesis With Concurrent Gastroesophageal Reflux Disease Induced by Low-Dose Liraglutide.

Ishihara Y, Nishiguchi S, Branch J, Tanaka E

Cureus16 Jul 2022Cited by 8 (Europe PMC)

PMID35983392PMCIDPMC9376210DOI10.7759/cureus.26916PepBankPUB-35983392

Summary

A 74-year-old woman with type 2 diabetes mellitus presented with nausea and abdomen distension. Four days prior, liraglutide 0.6 mg had been commenced. An abdominal computed tomography scan revealed gastric dilatation without mechanical obstruction which clinically suggested gastroparesis (GP). Her symptoms resolved after liraglutide discontinuation. A gastroscopy revealed reflux esophagitis. Taken together, GP may have developed along with reflux esophagitis due to liraglutide administration. Liraglutide's action inhibits gastric motility. Physicians should be cognizant of the side effects of GLP-1 agonists even in low dose in patients who have gastric emptying symptoms suggesting GP.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanCase report or seriesSafety outcome
In a 74-year-old woman with type 2 diabetes, gastric dilatation without mechanical obstruction, suggesting gastroparesis, appeared after low-dose liraglutide was started.
In plain wordsIn one older woman with type 2 diabetes, a low dose of liraglutide was followed by signs of slowed stomach emptying.
Peptide
Liraglutide
Outcome
IncreaseSuspected gastroparesis with gastric dilatation
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.6 mg · 4 daysAs given in this study (human).
Source sentences
Summary
An abdominal computed tomography scan revealed gastric dilatation without mechanical obstruction which clinically suggested gastroparesis (GP).
2 context sentences(design, population, supporting numbers)
Summary · context
Four days prior, liraglutide 0.6 mg had been commenced.
Summary · context
A 74-year-old woman with type 2 diabetes mellitus presented with nausea and abdomen distension.
Show in the study text Report a problemFND-3598339201
02HumanCase report or seriesSafety outcome
In a 74-year-old woman with type 2 diabetes, nausea and abdominal distension resolved after liraglutide was stopped.
In plain wordsIn one older woman with type 2 diabetes, nausea and a swollen belly went away after liraglutide was stopped.
Peptide
Liraglutide
Outcome
DecreaseSymptom resolution after liraglutide discontinuation
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.6 mg · 4 daysAs given in this study (human).
Source sentences
Summary
Her symptoms resolved after liraglutide discontinuation.
2 context sentences(design, population, supporting numbers)
Summary · context
Four days prior, liraglutide 0.6 mg had been commenced.
Summary · context
A 74-year-old woman with type 2 diabetes mellitus presented with nausea and abdomen distension.
Show in the study text Report a problemFND-3598339202
03HumanCase report or seriesSafety outcome
In a 74-year-old woman with type 2 diabetes, gastroscopy showed reflux esophagitis, which the authors judged may have developed alongside gastroparesis due to liraglutide.
In plain wordsIn one older woman with type 2 diabetes, a camera test showed acid reflux damage, which the authors linked to liraglutide.
Peptide
Liraglutide
Outcome
IncreaseReflux esophagitis
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.6 mg · 4 daysAs given in this study (human).
Source sentences
Summary
A gastroscopy revealed reflux esophagitis.
2 context sentences(design, population, supporting numbers)
Summary · context
Taken together, GP may have developed along with reflux esophagitis due to liraglutide administration.
Summary · context
A 74-year-old woman with type 2 diabetes mellitus presented with nausea and abdomen distension.
Show in the study text Report a problemFND-3598339203

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.